Search results for "profiling"

showing 10 items of 881 documents

Abstract A24: Bone marrow hematopoietic adaptation as a sensor of early, pre-invasive, epithelial malignancy

2018

Abstract Tumor development and progression is in part dependent on the ability of bystander cells, mostly of bone marrow (BM) origin, to establish a pro-tumorigenic microenvironment. We hypothesized that signs of the cross-talk between elements of the tumor microenvironment and the BM can be identified in the very early phases of cancer development, being finalized to the instruction of a tumor-promoting hematopoiesis. By integrating in situ BM histopathological and immunophenotypical analyses with flow cytometry and gene expression profiling of hematopoietic populations in a spontaneous mouse model of breast carcinogenesis (MMTV/NeuT) we investigated the occurrence and quality of modificat…

Cancer ResearchTumor microenvironmentStromal cellBiologyGene signatureGene expression profilingHaematopoiesisImmunophenotypingmedicine.anatomical_structureOncologyTumor progressionCancer researchmedicineBone marrowCancer Research
researchProduct

Abstract LB061: On-target peripheral and tumor immune microenvironment modulation in patients treated with lacnotuzumab (anti-CSF1, MCS110) + spartal…

2021

Abstract Background: The CSF-1/CSF-1R (colony-stimulating factor-1) pathway plays a significant role in the tumor microenvironment via regulation of tumor-associated macrophages (TAMs). Lacnotuzumab (MCS110) is a humanized monoclonal antibody against CSF-1. Lacnotuzumab may counteract the tumor suppressive microenvironment induced by CSF-1, potentially enhancing the efficacy of PD-1 inhibition. Methods: MCS110Z2102 is a phase 1b/2 study in cancer patients with advanced malignancies treated by lacnotuzumab combined with the PD-1 inhibitor spartalizumab. Eligible patients with previously treated advanced/metastatic solid tumors received 1, 3, 5, 7.5 and 10 mg/kg intravenous doses of lacnotuzu…

Cancer ResearchTumor microenvironmentbusiness.industryEndometrial cancerMelanomaCancermedicine.diseaseGene expression profilingBreast cancerOncologyPancreatic cancermedicineCancer researchCytotoxic T cellbusinessCancer Research
researchProduct

The p53 Tumor Suppressor Network Is a Key Responder to Microenvironmental Components of Chronic Inflammatory Stress

2005

Abstract Activation of the p53 network plays a central role in the inflammatory stress response associated with ulcerative colitis and may modulate cancer risk in patients afflicted with this chronic disease. Here, we describe the gene expression profiles associated with four microenvironmental components of the inflammatory response (NO•, H2O2, DNA replication arrest, and hypoxia) that result in p53 stabilization and activation. Isogenic HCT116 and HCT116 TP53−/− colon cancer cells were exposed to the NO• donor Sper/NO, H2O2, hypoxia, or hydroxyurea, and their mRNA was analyzed using oligonucleotide microarrays. Overall, 1,396 genes changed in a p53-dependent manner (P < 0.001), wit…

Cancer ResearchTumor suppressor geneColorectal cancerInflammationBiologymedicine.disease_causeArticleGene expressionmedicineHumansNitric Oxide DonorsInflammationReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingCell CycleHydrogen PeroxideCell cycleHypoxia (medical)Flow CytometryHCT116 Cellsmedicine.diseaseCell HypoxiaGene expression profilingOxidative StressOncologyImmunologyNitrogen OxidesSpermineTumor Suppressor Protein p53medicine.symptomOxidative stressCancer Research
researchProduct

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.

2009

SummaryDysregulation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway occurs frequently in human cancer. PTEN tumor suppressor or PIK3CA oncogene mutations both direct PI3K-dependent tumorigenesis largely through activation of the AKT/PKB kinase. However, here we show through phosphoprotein profiling and functional genomic studies that many PIK3CA mutant cancer cell lines and human breast tumors exhibit only minimal AKT activation and a diminished reliance on AKT for anchorage-independent growth. Instead, these cells retain robust PDK1 activation and membrane localization and exhibit dependency on the PDK1 substrate SGK3. SGK3 undergoes PI3K- and PDK1-dependent activation in PI…

Cancer Researchanimal structuresCell SurvivalClass I Phosphatidylinositol 3-KinasesAKT1AKT2Breast NeoplasmsCELLCYCLEBiologyProtein Serine-Threonine Kinasesmedicine.disease_causeArticle03 medical and health sciencesPhosphatidylinositol 3-Kinases0302 clinical medicineCell Line TumorNeoplasmsmedicinePTENHumansProtein kinase BneoplasmsPI3K/AKT/mTOR pathway030304 developmental biology0303 health sciencesGene Expression ProfilingPTEN PhosphohydrolasePyruvate Dehydrogenase Acetyl-Transferring KinaseCell Biology3. Good healthEnzyme ActivationOncology030220 oncology & carcinogenesisCancer cellMutationCancer researchbiology.proteinFemaleSignal transductionCarcinogenesisProto-Oncogene Proteins c-aktSignal TransductionCancer cell
researchProduct

Unknown primary tumors

2011

An unknown primary tumor (UPT) is defined by the presence of a metastatic cancer without a known primary site of origin despite a standardized diagnostic workup. Clinically, UPTs show rapid progression and early dissemination, with signs and symptoms related to the metastatic site. The molecular bases of their biology remain largely unknown, with no evidence as to whether they represent a distinct biological entity. Immunohistochemistry remain the best diagnostic tool in term of cost-effectiveness, but the time-consuming "algorithmic process" it relies on has led to the application of new molecular techniques for the identification of the primary site of UPTs. For example, several microarra…

Cancer Researchbusiness.industryGene Expression ProfilingBiological entityMEDLINETreatment optionsSigns and symptomsBioinformaticsFunctional imagingMicroRNAsOncologyUnknown primary tumors UPTImmunologyUnknown Primary TumorsGeneticsUnknown primaryAnimalsHumansNeoplasms Unknown PrimaryMedicinebusinessSite of originBiochimica et Biophysica Acta (BBA) - Reviews on Cancer
researchProduct

Next-Generation Genomic Profiling of Hepatocellular Adenomas: A New Era of Individualized Patient Care

2014

Hepatocellular adenomas (HCAs) are clinically relevant benign liver lesions that commonly occur in women on hormonal contraceptives. In this issue of Cancer Cell, Pilati and colleagues present an integrative multi-“omics”-based analysis of HCA and identify recurrent genetic alterations associated with adenoma-carcinoma transition and new drugable targets.

Cancer Researchmedicine.medical_specialtyCarcinoma HepatocellularGenomic profilingAdenomaMEDLINEBiologyBioinformaticsPatient careAdenoma Liver CellText miningInternal medicinemedicineCarcinomaAnimalsHumansbusiness.industryLiver NeoplasmsCell BiologyProtein-Tyrosine Kinasesmedicine.diseaseOmicsdigestive system diseasesNeoplasm ProteinsCell Transformation NeoplasticEndocrinologyOncologyCancer cellbusinessCancer Cell
researchProduct

Physiological mechanisms regulating the expression of endothelial-type NO synthase

2002

Although endothelial nitric oxide synthase (eNOS) is a constitutively expressed enzyme, its expression is regulated by a number of biophysical, biochemical, and hormonal stimuli, both under physiological conditions and in pathology. This review summarizes the recent findings in this field. Shear stress, growth factors (such as transforming growth factor-beta, fibroblast growth factor, vascular endothelial growth factor, and platelet-derived growth factor), hormones (such as estrogens, insulin, angiotensin II, and endothelin 1), and other compounds (such as lysophosphatidylcholine) upregulate eNOS expression. On the other hand, the cytokine tumor necrosis factor-alpha and bacterial lipopolys…

Cancer Researchmedicine.medical_specialtyNitric Oxide Synthase Type IIIPhysiologyRNA Stabilitymedicine.medical_treatmentClinical BiochemistryBiologyFibroblast growth factorBiochemistryGene Expression Regulation Enzymologicchemistry.chemical_compoundEnosInternal medicinemedicineAnimalsPromoter Regions GeneticRegulation of gene expressionBase SequenceGene Expression ProfilingGrowth factorbiology.organism_classificationActin cytoskeletonAngiotensin IICell biologyVascular endothelial growth factorEndocrinologychemistryNitric Oxide SynthaseSignal transductionSignal TransductionNitric Oxide
researchProduct

GADD45α is highly expressed in pancreatic ductal adenocarcinoma cells and required for tumor cell viability

2005

Pancreatic ductal adenocarcinoma is one of the most common causes of cancer death in the western civilization. Recently, NF-kappaB has been shown to be activated in pancreatic ductal adenocarcinoma through constitutive activation of IkappaB kinase (IKK). Inhibition of NF-kappaB by a super-inhibitor of NF-kappaB--delta-N-IkappaBalpha--resulted in impaired proliferation and induction of apoptosis, suggesting an important role of NF-kappaB in pancreatic tumorigenesis. Downstream target genes of IkappaBalpha have not been elucidated in pancreatic ductal adenocarcinoma in detail. Using expression profiling by cDNA array analysis of pancreatic ductal adenocarcinoma cell lines stably transfected w…

Cancer Researchmedicine.medical_specialtyPancreatic diseaseCell SurvivalDown-RegulationCell Cycle ProteinsIκB kinaseAdenocarcinomaBiologymedicine.disease_causeDownregulation and upregulationPancreatic cancerInternal medicinemedicineHumansCell ProliferationCell growthGene Expression ProfilingNF-kappa BNuclear Proteinsmedicine.diseaseI-kappa B KinasePancreatic NeoplasmsEndocrinologyOncologyApoptosisCancer researchRNA InterferenceCA19-9CarcinogenesisCarcinoma Pancreatic DuctalInternational Journal of Cancer
researchProduct

Expression pattern of the urokinase-plasminogen activator system in rat DS-sarcoma: Role of oxygenation status and tumour size

2002

The urokinase plasminogen activator system plays a central role in malignant tumour progression. Both tumour hypoxia and enhancement of urokinase plasminogen activator, urokinase plasminogen activator-receptor and plasminogen activator inhibitor type 1 have been identified as adverse prognostic factors. Upregulation of urokinase plasminogen activator or plasminogen activator inhibitor type 1 could present means by which hypoxia influences malignant progression. Therefore, the impact of hypoxia on the expression pattern of the urokinase plasminogen activator system in rat DS-sarcoma in vivo and in vitro was examined. In the in vivo setting, tumour cells were implanted subcutaneously into rat…

Cancer Researchplasminogen activator inhibitor type-1DS-sarcomaEnzyme-Linked Immunosorbent AssayReceptors Cell Surfaceurokinase plasminogen activator receptorBiologyReceptors Urokinase Plasminogen Activatorchemistry.chemical_compoundDownregulation and upregulationIn vivoPlasminogen Activator Inhibitor 1Tumor Cells CulturedmedicineAnimalsExperimental TherapeuticsZymographyRNA Messengerurokinase plasminogen activatorHyperoxiaUrokinasehypoxiaReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingSarcomamalignant progressionUrokinase-Type Plasminogen ActivatorMolecular biologyIn vitroRatsGene Expression Regulation NeoplasticOxygenUrokinase receptorOncologychemistryOrgan SpecificityPlasminogen activator inhibitor-1medicine.symptommedicine.drugBritish Journal of Cancer
researchProduct

Pharmacogenomics of Cameroonian traditional herbal medicine for cancer therapy

2011

Abstract Ethnopharmacological relevance A socio-economic burden associated with cancers is reported in Africa. Ethnopharmacological usages such as immune and skin disorders, inflammatory, and others chould be considered when selecting plants used to treat cancer, since these reflect disease states bearing relevance to cancer or a cancer symptoms. Materials and methods Documented compounds of Cameroonian medicinal plants were used as keywords in the National Cancer Institute (NCI) database to establish a library of cytotoxic compounds. Cellular and pharmacogenomic profiling was then performed for the 10 most cytotoxic natural products. By COMPARE and hierarchical cluster analyses, candidate …

Candidate geneMicroarrayCell SurvivalPharmacologyInhibitory Concentration 50chemistry.chemical_compoundCell Line TumorDrug DiscoveryAnimalsCluster AnalysisHumansMedicineCameroonRNA MessengerMedicinal plantsMedicine African TraditionalPharmacologyPlants MedicinalNatural productDose-Response Relationship DrugTraditional medicinebiologybusiness.industryGene Expression ProfilingPlumbaginbiology.organism_classificationAntineoplastic Agents PhytogenicGene Expression Regulation NeoplasticGene expression profilingchemistryDrug Resistance NeoplasmPharmacogeneticsPharmacogenomicsPlant PreparationsDiospyros crassiflorabusinessJournal of Ethnopharmacology
researchProduct